Ryvu Therapeutics S.A. Stock price

Equities

RVU

PLSELVT00013

Biotechnology & Medical Research

Market Closed - Warsaw S.E. 12:55:46 2024-03-28 pm EDT 5-day change 1st Jan Change
55.2 PLN -0.54% Intraday chart for Ryvu Therapeutics S.A. -3.83% -4.00%
Sales 2024 * 152M 38.08M Sales 2025 * 218M 54.55M Capitalization 1.28B 320M
Net income 2024 * -124M -31.1M Net income 2025 * -119M -29.84M EV / Sales 2024 * 7.92 x
Net cash position 2024 * 73.62M 18.46M Net Debt 2025 * 18.41M 4.62M EV / Sales 2025 * 5.95 x
P/E ratio 2024 *
-13.8 x
P/E ratio 2025 *
-12.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.54%
More Fundamentals * Assessed data
Dynamic Chart
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting CI
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS CI
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml CI
Transcript : Ryvu Therapeutics S.A. - Special Call
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023 CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Ryvu Therapeutics S.A. - Special Call
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120 CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ryvu and TIM to enter Warsaw's mWIG40 index RE
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting CI
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics MT
More news

Latest transcript on Ryvu Therapeutics S.A.

1 day-0.54%
1 week-3.83%
Current month-7.07%
1 month-7.85%
3 months-7.69%
6 months-12.10%
Current year-4.00%
More quotes
1 week
55.10
Extreme 55.1
57.40
1 month
55.10
Extreme 55.1
59.90
Current year
53.50
Extreme 53.5
61.00
1 year
53.50
Extreme 53.5
72.40
3 years
22.20
Extreme 22.2
72.40
5 years
22.20
Extreme 22.2
78.00
10 years
8.56
Extreme 8.56
78.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 06-12-31
Chief Tech/Sci/R&D Officer - 22-01-31
Chief Operating Officer 38 12-12-31
Members of the board TitleAgeSince
Director/Board Member 72 -
Director/Board Member 69 -
Director/Board Member - -
More insiders
Date Price Change Volume
24-03-28 55.2 -0.54% 4,408
24-03-27 55.5 -1.25% 4,299
24-03-26 56.2 -1.06% 2,501
24-03-25 56.8 -0.53% 1,010
24-03-22 57.1 -0.35% 1,046

Delayed Quote Warsaw S.E., March 28, 2024 at 12:55 pm EDT

More quotes
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company's portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
55.2 PLN
Average target price
71.88 PLN
Spread / Average Target
+30.21%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Ryvu Therapeutics S.A. - Warsaw S.E.